25 September, 2020

The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.

This webinar will take place on Saturday 17th October at 2:00pm EST. You can find a copy of the flyer in Word version here or in PDF version here

Back to News

We can’t do what we do without you!

Other News

March 2026 CEO Message from Jonathan Brookes

As I complete my second month as CEO of Retina Australia, I’ve been focused on two key priorities: building...

Presentation to Professor Michael Kalloniatis of the 2025 Hall of Fame Award

Retina Australia was proud to recognise Professor Michael Kalloniatis...

Inaugural Message from CEO Jonathan Brookes.

I am thrilled to write to you as the new CEO of Retina Australia. It has been an exciting...